Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A5MC
|
||||
| Former ID |
DCL000169
|
||||
| Drug Name |
MLN8054
|
||||
| Synonyms |
ZZL; MLN-8054
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Millenium; Takeda
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C25H15ClF2N4O2
|
||||
| InChI |
InChI=1S/C25H15ClF2N4O2/c26-15-6-9-17-18(10-15)23(21-19(27)2-1-3-20(21)28)29-11-14-12-30-25(32-22(14)17)31-16-7-4-13(5-8-16)24(33)34/h1-10,12H,11H2,(H,33,34)(H,30,31,32)
|
||||
| InChIKey |
HHFBDROWDBDFBR-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 869363-13-3
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16817521, 23803070, 50100109, 75812624, 85240458, 87325745, 92728686, 103565670, 103904597, 117695998, 123055394, 124756998, 125163803, 131480681, 134338844, 134964414, 135686180, 135686181, 135686202, 135686203, 136340201, 136367298, 136920349, 137242800, 137739931, 152258105, 152344040, 160646944, 162011816, 162037433, 162723440, 163642777, 164193990, 164763083, 170496031, 174006403, 174531092, 177749042, 178102323, 180190865, 186022471, 198945325, 215776778, 223258872, 223579841, 223704701, 225331045, 226922686, 242059849, 244479327
|
||||
| Target and Pathway | |||||
| Target(s) | Aurora kinase A | Target Info | Inhibitor | [536401], [536474], [551717] | |
| KEGG Pathway | Oocyte meiosis | ||||
| Pathway Interaction Database | Aurora B signaling | ||||
| Signaling by Aurora kinases | |||||
| Integrin-linked kinase signaling | |||||
| PLK1 signaling events | |||||
| Aurora A signaling | |||||
| References | |||||
| Ref 522281 | ClinicalTrials.gov (NCT00652158) A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies. U.S. National Institutes of Health. | ||||
| Ref 541037 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5696). | ||||
| Ref 536401 | MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol. 2007 Jun;27(12):4513-25. Epub 2007 Apr 16. | ||||
| Ref 536474 | A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22. | ||||
| Ref 551717 | Clinical pipeline report, company report or official report of Takeda (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.